Digital Rectal Examination and the Diagnosis of Prostate Cancer-a Study Based on 8 Years and Three Screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam

European Urology

Volumn 55, Issue 1, 2009, Pages 139-147

  Gosselaar, Claartje ^a   Roobol, Monique J ^a   van den Bergh, Roderick C N ^a   Wolters, Tineke ^a   Schröder, Fritz H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Digital rectal examination; Prostate cancer; Screening; Screening interval

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; DIGITAL RECTAL EXAMINATION; EUROPE; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NETHERLANDS; PERIODIC MEDICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZATION; REPEAT PROCEDURE; TRANSRECTAL ULTRASONOGRAPHY;

AGED; BIOPSY; DIGITAL RECTAL EXAMINATION; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 56249096938     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.03.079     Document Type: Article

References (27)

1. Carvalhal G.F., Smith D.S., Mager D.E., Ramos C., and Catalona W.J. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less. J Urol 161 (1999) 835-839
2. Catalona W.J., Richie J.P., Ahmann F.R., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151 (1994) 1283-1290
3. Rietbergen J.B., Kranse R., Kirkels W.J., De Koning H.J., and Schroder F.H. Evaluation of prostate-specific antigen, digital rectal examination and transrectal ultrasonography in population-based screening for prostate cancer: improving the efficiency of early detection. Br J Urol 79 Suppl 2 (1997) 57-63
4. Schröder F.H., Alexander F.E., Bangma C.H., Hugosson J., and Smith D.S. Screening and early detection of prostate cancer. Prostate 44 (2000) 255-263
5. Schröder F.H., van der Maas P., Beemsterboer P., et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 90 (1998) 1817-1823
6. Schröder F.H., Roobol-Bouts M., Vis A.N., van der Kwast T., and Kranse R. Prostate-specific antigen-based early detection of prostate cancer-validation of screening without rectal examination. Urology 57 (2001) 83-90
7. Thompson I.M., Ankerst D.P., Chi C., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98 (2006) 529-534
8. Borden Jr. L.S., Wright J.L., Kim J., Latchamsetty K., and Porter C.R. An abnormal digital rectal examination is an independent predictor of Gleason > or = 7 prostate cancer in men undergoing initial prostate biopsy: a prospective study of 790 men. Br J Urol Int 99 (2007) 559-563
9. Roobol M.J., Kirkels W.J., and Schroder F.H. Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). Br J Urol Int 92 Suppl 2 (2003) 48-54
10. Eskew L.A., Bare R.L., and McCullough D.L. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 157 (1997) 199-203
11. Stamey T.A. Making the most out of six systematic sextant biopsies. Urology 45 (1995) 2-12
12. Lerner S.E., Seay T.M., Blute M.L., Bergstralh E.J., Barrett D., and Zincke H. Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis. J Urol 155 (1996) 821-826
13. Stamey T.A., Sozen T.S., Yemoto C.M., and McNeal J.E. Classification of localized untreated prostate cancer based on 791 men treated only with radical prostatectomy: common ground for therapeutic trials and TNM subgroups. J Urol 159 (1998) 2009-2012
14. Ghavamian R., Blute M.L., Bergstralh E.J., Slezak J., and Zincke H. Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy. Urology 54 (1999) 105-110
15. Ramos C.G., Carvalhal G.F., Smith D.S., Mager D.E., and Catalona W.J. Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer. J Urol 161 (1999) 1525-1529
16. Roobol M.J., Grenabo A., Schroder F.H., and Hugosson J. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. J Natl Cancer Inst 99 (2007) 1296-1303
17. Kranse R., Beemsterboer P., Rietbergen J., Habbema D., Hugosson J., and Schroder F.H. Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region). Prostate 39 (1999) 316-322
18. Beemsterboer P.M., Kranse R., de Koning H.J., Habbema J.D., and Schroder F.H. Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam). Int J Cancer 84 (1999) 437-441
19. Littrup P.J., and Bailey S.E. Prostate cancer: the role of transrectal ultrasound and its impact on cancer detection and management. Radiol Clin North Am 38 (2000) 87-113
20. Terris M.K., Freiha F.S., McNeal J.E., and Stamey T.A. Efficacy of transrectal ultrasound for identification of clinically undetected prostate cancer. J Urol 146 (1991) 78-84
21. Postma R., Schröder F.H., van Leenders G.J., et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC) - Section Rotterdam: a comparison of two rounds of screening. Eur Urol 52 (2007) 89-97
22. Narain V., Bianco Jr. F.J., Grignon D.J., Sakr W.A., Pontes J.E., and Wood Jr. D.P. How accurately does prostate biopsy Gleason score predict pathologic findings and disease free survival?. Prostate 49 (2001) 185-190
23. Catalona W.J., Bartsch G., Rittenhouse H.G., et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol 171 (2004) 2239-2244
24. Vis A.N., Hoedemaeker R.F., Roobol M., van der Kwast T.H., and Schroder F.H. Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml). Prostate 47 (2001) 252-261
25. Armatys S.A., Koch M.O., Bihrle R., Gardner T.A., and Cheng L. Is it necessary to separate clinical stage T1c from T2 prostate adenocarcinoma?. Br J Urol Int 96 (2005) 777-780
26. Roobol M.J., Schroder F.H., and Kranse R. A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam). Prostate 66 (2006) 604-612
27. van der Cruijsen-Koeter I.W., Roobol M.J., Wildhagen M.F., van der Kwast T.H., Kirkels W.J., and Schroder F.H. Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam. Urology 68 (2006) 615-620